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Blood exchange transfusion (ET) in newborns is an age-old intervention which involves the replacement of affected neonate’s blood with compatible donor 
blood. ET was primarily used in rhesus hemolytic disease of 
newborn (RHDN) to decrease the mortality associated with it 
and prevent sequelae of kernicterus due to hyperbilirubinemia 
in newborns [1]. Subsequently, its use has been extended to 
hyperbilirubinemia due to other hemolytic and non-hemolytic 
causes, severe sepsis, severe fluid and electrolyte disturbances, 
inborn errors of metabolism, disseminated intravascular 
coagulation, severe anemia and polycythemia [2]. With 
improved prenatal care of rhesus (Rh) negative isoimmunized 
pregnancies (anti-Rh D immunoglobulin and intrauterine 
transfusions) as well as postnatal intensive phototherapy, there 
is marked decrease in the requirement of ET in last few decades. 
Revised American Academy of Pediatrics (AAP) guidelines 
for hyperbilirubinemia and use of postnatal immunoglobulin in 
RHD have also contributed to the decline [3-5].
As a result, ET has become a rarely performed procedure 
in nearly every developed country with a rate of 3/100,000 live 
births in the United States [6]. Consequently, skills required for 
this life-saving procedure has declined leading to concerns for the 
adverse events associated with it. The associated complications 
are thrombocytopenia, electrolyte and acid-base disturbances, 
cardiovascular instability, hypothermia, arrhythmias, apnea, 
seizures, and sepsis. Despite declining indications, ET still remains 
an emergency rescue procedure for severe hyperbilirubinemia in 
many resource-limited developing countries [2]. Late referrals, 
delayed diagnosis of severe hyperbilirubinemia and substandard 
phototherapy devices are some of the main reasons. This study was 
conducted with the aim to describe indications and complications 
of ET at a tertiary care center in North India.
MATERIALS AND METHODS
This was a retrospective observational cohort study conducted 
in a 20-bedded level III neonatology unit of a tertiary care 
teaching institute. All neonates who underwent blood ET from 
July 2014 to May 2019 were screened for inclusion. Those 
who had undergone double or single-volume ET were included 
in the study. Newborns, who underwent partial ET for severe 
anemia or polycythemia and those with incomplete records, 
were excluded from the study. For hyperbilirubinemia due to 
RHDN, indications for ET were cord hematocrit (Hct) <30% or 
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cord total serum bilirubin (TSB) >5 mg/dl; rate of rise of TSB 
>1 mg/dl/h despite intensive PT; any TSB >12 mg/dl in the first 
24 h and TSB >20 mg/dl in the neonatal period; and the presence 
of hydrops at birth or history of previous sibling requiring 
exchange due to Rh isoimmunization and index patient born with 
pallor, hepatosplenomegaly, and positive direct Coombs test.
For other neonates with hyperbilirubinemia, the AAP 2004 
recommendations for the infants ≥35 weeks of gestation [7] and 
weight-based cut-offs for <35 weeks were used [8]. All neonates 
with hyperbilirubinemia were given intensive phototherapy unit 
as per unit protocol. Compatible blood that was cross-matched 
with both newborn and mother was used. ET was done using 
freshly collected (<7 days) packed red blood cells (PRBC) and 
plasma that was reconstituted in the blood bank and irradiated 
before the procedure.
Data were retrieved from medical records of the patient and 
included maternal details, newborn’s demographics, indications 
for performing the first ET, procedure details, complications 
attributable to ET (occurring within 72 h after the procedure), 
and outcome at discharge. Institute ethical committee approved 
the project. Data were analyzed using SPSS version 20 (IBM 
Inc., Armonk, NY, USA). Categorical data were expressed as 
percentages and numerical data as median (interquartile range 
IQR).
RESULTS
A total of 2310 neonates were admitted during the study period. 
A total of 77 (3.3%) neonates underwent 103 ETs during the 
study period, an average rate of 23.3 ETs per year. The baseline 
characteristics of study population are shown in Table 1.
Table 2 describes detail of the exchange procedure in study 
population.
Hyperbilirubinemia was the most common indication for ET 
in 53 (68.8%) neonates. RHDN was seen in 43 (55.8%) and was 
the most common etiology for hyperbilirubinemia. A total of 
42 (54.5) neonates underwent ET within first 12 h of life with 
median age at first ET 11 h (IQR8-168). A total of 20 (25.9%) 
neonates required more than one ET. A total of 77 adverse events 
related to ET were seen in 53 (68.8%) neonates as described in 
Table 3.
The most  common adverse event noted was thrombocytopenia 
followed by dyselectrolytemia and sepsis. Bilirubin-induced 
neurological dysfunction (BIND) was seen in 8 (10.4%) 
newborns; of these 7 were outborn babies who had BIND at 
admission. Overall, 7 (9.1%) neonates died in study and was not 
related to ET procedure.
Table 1: Baseline characteristics of the study population (n=77)
Variables n (%) 
Gestational age at birth (weeks) 36 (34+2–37+2)*
Birth weight (grams) 2514 (2155–2800)*
Male gender 49 (63.6)
Place of delivery
Inborn 54 (70.1)
Outborn 23 (29.9)
Mode of delivery
Cesarean section 58 (75.3)
Vaginal 19 (24.7)
Intrauterine transfusions 38 (49.3)
Duration of hospital stay (days) 13 (9–20)*
Mortality 7 (9.1)
Re-admission 30 (39)
Reasons for readmission
Top up transfusion 19 (24.7)
Phototherapy 4 (5.2)
Other 7 (9.1)
* Median (interquartile range) 
Table 2: Parameters related to exchange transfusion in the study 
population (n=77)
Variables n (%)
Indications
Hyperbilirubinemia 53 (68.8)
Hyperbilirubinemia+severe anemia 9 (11.7)
Severe sepsis  7 (9.1)
Severe anemia  6 (7.8)
Hyperbilirubinemia+severe sepsis  2 (2.6)
Number  1 (1–2)*
Neonates requiring more than one ET 20 (25.9)
Type of ET
Double volume 70 (90.9)
Single volume  6 (7.8)
Both  1 (1.3)
Route 
Central (umbilical) 60 (77.9)
Peripheral 14 (18.1)
Both  3 (3.8)
Age at first ET (hours) 11 (8–168)*
Duration (hours) 60 (57–90)*
Peak TSB (n=53) 15.1 (12.3–22.2)*
Etiology of hyperbilirubinemia n=64 (83.1)
Rhesus hemolytic disease 43 (55.8)
ABO incompatibility  5 (6.5)
Miscellaneous 16 (20.7)
ET- exchange transfusion, TSB-total serum bilirubin
Table 3: Complications related to exchange transfusion (n=77)
Variables n (%) 
Thrombocytopenia 40 (51.9)
Dyselectrolytemia 18 (23.7)
Hypocalcemia 16 (20.7)
Hyponatremia 2 (2.5)
Sepsis 8 (10.3)
Hemodynamic disturbances 5 (6.5)
Miscellaneous (apnea, feed intolerance, necrotizing 
enterocolitis, coagulopathy, hypoglycemia)
6 (7.7)
More than one adverse event 17 (22)
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DISCUSSION
This retrospective study describes the profile of neonates 
requiring ET and its complications. ET was introduced in 1950’s 
as a gold standard treatment for the management of newborns 
affected with severe hyperbilirubinemia due to RHDN [1]. 
The current consensus on performing ET depends on weighing 
balance between the risks of kernicterus versus adverse effects of 
procedure [9]. Overall, 3.3% admitted neonates underwent ET in 
this study which is similar to published literature [10-12] but less 
than that reported by Salas et al. [13] who reported ET in 15.5%. 
The difference could be due to changing practices across time and 
different demographic profile of patients requiring ET. RHDN was 
the most common etiology for ET in our study which is in contrast 
to other studies reported in literature [10-11,13-24]. Only three 
studies [25-27] reported it as the most common etiology for ET.
Even though the incidence of RHDN decreased across the 
globe, the disease is still seen in many developing countries. 
The possible reasons could be suboptimal antenatal care, poor 
affordability of anti-Rh D-globulin, lack of awareness among 
rural population for seeking antenatal care, and referral bias. 
Many studies reported idiopathic [14-16,19,21-22] cause of 
hyperbilirubinemia requiring ET which was followed by ABO 
incompatibility [17,20,23]. ET was done in 9.1% neonates with 
severe sepsis in the study. Role of ET in severe sepsis was recently 
studied by a randomized trial which demonstrated a trend toward 
decrease in mortality and improvement in immunoglobulin and 
complement C3 levels and acid-base status following ET [28].
This study demonstrated adverse events in 53 (68.8%) newborns. 
Available literature reports variable incidence of adverse events 
related to ET ranging from 13% to 93.1% [12-15,19,21-24,27]. 
The different incidence could be explained by variation in the 
definitions used, level of sickness, etiologic profile of neonates, and 
varying expertise for performing the procedure. The most common 
complication noted was thrombocytopenia (51.9%) which is similar 
to the published studies [13,15,20,27-29]. Thrombocytopenia 
following ET occurs due to replacement of whole blood with PRBC, 
which is deficient in platelets as well as activation of coagulation 
system leading to consumptive coagulopathy [24].
Hypocalcemia is one of the common biochemical abnormalities after 
ET and its incidence varies from 11.5% to 48.3% [13-14,20,22,24,27-29]. 
Hypocalcemia (20.7%) was the second most common adverse event 
noted in this study. The possible mechanism includes binding of ionic 
calcium and magnesium by citrate which is used as anticoagulant in 
donor blood. Most complications were transient and manageable. 
Although overall mortality was 9.1%, none could be directly attributable 
to ET. The reported mortality due to ET varies from 0 to 3.3% and our 
results are comparable to these studies [13-15,19,20-24,27].
The present study adds to limited recent literature available 
from India, describing indications and complications of ET. 
Although ET is relatively safe, high incidence of complications 
mandates strict monitoring of both clinical and laboratory 
parameters during and after the procedure. Limitations include 
retrospective nature of the study and being a single-center study, 
the data might not be generalizable to other parts of India.
CONCLUSION
This study identifies rhesus hemolytic disease of the newborn 
as the most common etiology for exchange transfusion in this 
part of country. The incidence of adverse events was moderately 
high which suggests that ET should be performed under settings 
where expertise for performing and managing complications is 
available.
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